Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

C4 And Google's Calico Enter Mysterious Alliance On 'Diseases Of Aging'

While details are scant, the five-year collaboration will pair C4's targeted protein degradation approach with Calico's focus on diseases of aging. Privately held C4 otherwise is aiming to bring its first Degronomid candidate into the clinic in 2018.

Deals Companies Commercial

Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

Commercial Market Intelligence Research and Development Strategies

CHMP Opinions: Opdivo Sees Keytruda's Hodgkin's And Raises It Head & Neck

Merck & Co and Bristol Myers Squibb's rival anti-PD1 products continue their game of one-upmanship with each gaining a new indication in the latest round of EU CHMP opinions.

Approvals Drug Review Cancer

Pfizer On Obamacare Rewind: No Short-Term Impact On Industry

Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.

Policy Pricing Debate United States
Advertisement


 Recent Tweets from Scrip


Commercial Explore this Topic

C4 And Google's Calico Enter Mysterious Alliance On 'Diseases Of Aging'

While details are scant, the five-year collaboration will pair C4's targeted protein degradation approach with Calico's focus on diseases of aging. Privately held C4 otherwise is aiming to bring its first Degronomid candidate into the clinic in 2018.

Deals Companies Commercial

Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

Commercial Market Intelligence Research and Development Strategies

Latest From Commercial

Finance Watch: Raising Cash Before Trump Bump Deflates, La Jolla Grabs $125m, Akcea Seeks $100m IPO

La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics entered an agreement to sell up to $100m in stock, Ionis's Akcea makes IPO plans, and $64m in Series B and other cash for SutroVax tops the list of recent venture capital rounds.

Commercial Companies

Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear

The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.

Leadership Companies

Confidence High As AstraZeneca Adds Asia To Benralizumab Territories

In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.

Asia Pacific Deals

Accusations Fly In Messy Ranbaxy Compensation Battle

The ongoing fight by Daiichi Sankyo for compensation from India’s Singh brothers over the company’s disastrous purchase of generic drugs giant Ranbaxy has heated up, with the Japanese firm now accusing the tycoons of not telling the truth about the value of assets meant to serve as security for damages.

India Legal Issues

Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré

Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.

Commercial Companies

Quick Commercial Standouts Lacking Among 2016 US Launches

The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.

Launches Commercial

Policy & Regulation Explore this Topic

Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month

First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.

Approvals Regulation Pricing Strategies

Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer

Pfizer got Bavencio to market by focusing on an unmet need, but the PD-L1 inhibitor is still a few years behind, competing with other checkpoint inhibitors over more valuable indications.

Approvals ImmunoOncology

Biogen Secures First-Round Patent Win For Tecfidera; One More To Go

PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.

Intellectual Property Legal Issues

Which Pharma Firm Increases US Prices The Most?

Transparency reports from companies aim to change conversation from prices to discounts, but also invite comparisons. Lilly, for example, saw a higher average list price increase in 2016 than Merck and Janssen, but its net prices grew by less than the others.

Pricing Debate Policy

Research & Development Explore this Topic

Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic

With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.

Approvals Clinical Trials Regulation

Latest From Research & Development

Newron Needs To Up Ante In Large-Scale Schizophrenia Studies

Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.

Clinical Trials Neurology

Xenon Down On Novel Acne Treatment Failure

Xenon Pharmaceuticals' attempts to treat acne with a SCD-1 inhibitor have met with failure at the Phase II stage, casting doubt on the therapeutic strategy and wiping more than 50% of the company's share price.

Clinical Trials Research & Development

Sumagen’s World First Killed Whole HIV Vaccine Set For Phase II

After a positive outcome from a US Phase I study, South Korea's Sumagen is stepping closer to the launch of the world's first killed-whole HIV vaccine with potential to both prevent and treat AIDS.

Research & Development Clinical Trials
UsernamePublicRestriction

Register